Titre : Déplétion lymphocytaire

Déplétion lymphocytaire : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Déplétion lymphocytaire : Questions médicales les plus fréquentes", "headline": "Déplétion lymphocytaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Déplétion lymphocytaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-06", "dateModified": "2026-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Déplétion lymphocytaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Immunosuppression thérapeutique", "url": "https://questionsmedicales.fr/mesh/D007165", "about": { "@type": "MedicalCondition", "name": "Immunosuppression thérapeutique", "code": { "@type": "MedicalCode", "code": "D007165", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E05.478.610" } } }, "about": { "@type": "MedicalCondition", "name": "Déplétion lymphocytaire", "alternateName": "Lymphocyte Depletion", "code": { "@type": "MedicalCode", "code": "D008212", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Huajia Zhang", "url": "https://questionsmedicales.fr/author/Huajia%20Zhang", "affiliation": { "@type": "Organization", "name": "Clinical Research Division and." } }, { "@type": "Person", "name": "Robert H Pierce", "url": "https://questionsmedicales.fr/author/Robert%20H%20Pierce", "affiliation": { "@type": "Organization", "name": "Clinical Research Division and." } }, { "@type": "Person", "name": "A McGarry Houghton", "url": "https://questionsmedicales.fr/author/A%20McGarry%20Houghton", "affiliation": { "@type": "Organization", "name": "Clinical Research Division and." } }, { "@type": "Person", "name": "Jeffrey D Lifson", "url": "https://questionsmedicales.fr/author/Jeffrey%20D%20Lifson", "affiliation": { "@type": "Organization", "name": "AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America." } }, { "@type": "Person", "name": "Alayna Mellott", "url": "https://questionsmedicales.fr/author/Alayna%20Mellott", "affiliation": { "@type": "Organization", "name": "Department of Neuroscience, Cell Biology and Physiology, Boonshoft School of Medicine and College of Science and Mathematics, Wright State University, Dayton, OH, 45435, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia.", "datePublished": "2023-05-09", "url": "https://questionsmedicales.fr/article/37160316", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/mcs.a006241" } }, { "@type": "ScholarlyArticle", "name": "Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.", "datePublished": "2023-05-12", "url": "https://questionsmedicales.fr/article/37187201", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2352-3026(23)00073-X" } }, { "@type": "ScholarlyArticle", "name": "CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome.", "datePublished": "2024-07-20", "url": "https://questionsmedicales.fr/article/39181858", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clml.2024.07.006" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.", "datePublished": "2024-06-06", "url": "https://questionsmedicales.fr/article/38840327", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/FTD.0000000000001228" } }, { "@type": "ScholarlyArticle", "name": "Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.", "datePublished": "2023-12-25", "url": "https://questionsmedicales.fr/article/38176305", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.breast.2023.103668" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Techniques d'investigation", "item": "https://questionsmedicales.fr/mesh/D008919" }, { "@type": "ListItem", "position": 3, "name": "Techniques immunologiques", "item": "https://questionsmedicales.fr/mesh/D007158" }, { "@type": "ListItem", "position": 4, "name": "Immunosuppression thérapeutique", "item": "https://questionsmedicales.fr/mesh/D007165" }, { "@type": "ListItem", "position": 5, "name": "Déplétion lymphocytaire", "item": "https://questionsmedicales.fr/mesh/D008212" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Déplétion lymphocytaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Déplétion lymphocytaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-04-29", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Déplétion lymphocytaire", "description": "Comment diagnostiquer la déplétion lymphocytaire ?\nQuels tests sanguins sont nécessaires ?\nQuels signes indiquent une déplétion lymphocytaire ?\nLa biopsie est-elle nécessaire ?\nQuels sont les critères de diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D008212?page=388#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Déplétion lymphocytaire", "description": "Quels sont les symptômes courants ?\nLa déplétion lymphocytaire cause-t-elle des douleurs ?\nY a-t-il des symptômes spécifiques chez les enfants ?\nComment la déplétion lymphocytaire affecte-t-elle le système immunitaire ?\nPeut-on avoir des symptômes sans déplétion ?", "url": "https://questionsmedicales.fr/mesh/D008212?page=388#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Déplétion lymphocytaire", "description": "Peut-on prévenir la déplétion lymphocytaire ?\nLes vaccinations aident-elles ?\nY a-t-il des habitudes de vie à adopter ?\nLes contrôles médicaux réguliers sont-ils importants ?\nComment éviter les infections ?", "url": "https://questionsmedicales.fr/mesh/D008212?page=388#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Déplétion lymphocytaire", "description": "Quels traitements sont disponibles ?\nLa transfusion de lymphocytes est-elle une option ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nComment surveiller l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D008212?page=388#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Déplétion lymphocytaire", "description": "Quelles complications peuvent survenir ?\nLa déplétion lymphocytaire augmente-t-elle le risque de cancer ?\nComment gérer les infections graves ?\nLes maladies auto-immunes sont-elles liées ?\nY a-t-il des risques à long terme ?", "url": "https://questionsmedicales.fr/mesh/D008212?page=388#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Déplétion lymphocytaire", "description": "Quels sont les facteurs de risque principaux ?\nL'âge influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes traitements anticancéreux sont-ils un facteur ?\nLe stress chronique influence-t-il le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D008212?page=388#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la déplétion lymphocytaire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un hémogramme et des tests immunologiques sont utilisés pour évaluer les niveaux de lymphocytes." } }, { "@type": "Question", "name": "Quels tests sanguins sont nécessaires ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de numération des lymphocytes et des marqueurs immunitaires sont essentiels." } }, { "@type": "Question", "name": "Quels signes indiquent une déplétion lymphocytaire ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une diminution des lymphocytes et des infections fréquentes peuvent indiquer cette condition." } }, { "@type": "Question", "name": "La biopsie est-elle nécessaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être réalisée pour évaluer la fonction lymphocytaire dans certains cas." } }, { "@type": "Question", "name": "Quels sont les critères de diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent une numération lymphocytaire inférieure à la normale et des symptômes cliniques." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, infections récurrentes et fièvre persistante." } }, { "@type": "Question", "name": "La déplétion lymphocytaire cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des douleurs dues à des infections ou des inflammations associées." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques chez les enfants ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les enfants peuvent présenter des infections fréquentes et un retard de croissance." } }, { "@type": "Question", "name": "Comment la déplétion lymphocytaire affecte-t-elle le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle affaiblit le système immunitaire, rendant l'individu plus vulnérable aux infections." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans déplétion ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains symptômes peuvent être présents sans déplétion lymphocytaire, comme la fatigue." } }, { "@type": "Question", "name": "Peut-on prévenir la déplétion lymphocytaire ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention dépend de la cause; éviter les infections et maintenir une bonne santé est crucial." } }, { "@type": "Question", "name": "Les vaccinations aident-elles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent renforcer le système immunitaire et prévenir certaines infections." } }, { "@type": "Question", "name": "Y a-t-il des habitudes de vie à adopter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Adopter une alimentation équilibrée, faire de l'exercice et gérer le stress sont bénéfiques." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes immunitaires." } }, { "@type": "Question", "name": "Comment éviter les infections ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Pratiquer une bonne hygiène, éviter les foules et se faire vacciner aide à prévenir les infections." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunoglobulines, des antibiotiques et des thérapies ciblées." } }, { "@type": "Question", "name": "La transfusion de lymphocytes est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la transfusion de lymphocytes peut être envisagée dans certains cas de déplétion sévère." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les corticostéroïdes peuvent aider à réduire l'inflammation et à restaurer les lymphocytes." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements expérimentaux incluent des thérapies géniques et des médicaments immunomodulateurs." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins réguliers et l'évaluation des symptômes cliniques sont nécessaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections graves, des maladies auto-immunes et des cancers." } }, { "@type": "Question", "name": "La déplétion lymphocytaire augmente-t-elle le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut augmenter le risque de certains cancers en raison d'une immunité affaiblie." } }, { "@type": "Question", "name": "Comment gérer les infections graves ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement précoce avec des antibiotiques et une surveillance étroite sont essentiels." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles liées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la déplétion lymphocytaire peut être associée à des maladies auto-immunes en raison d'un déséquilibre immunitaire." } }, { "@type": "Question", "name": "Y a-t-il des risques à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des risques à long terme incluent des infections chroniques et des complications liées aux traitements." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque principaux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des maladies auto-immunes, des traitements immunosuppresseurs et des infections virales." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru de déplétion lymphocytaire en raison d'un système immunitaire affaibli." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies immunitaires peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les traitements anticancéreux sont-ils un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements anticancéreux peuvent entraîner une déplétion lymphocytaire en raison de leur nature immunosuppressive." } }, { "@type": "Question", "name": "Le stress chronique influence-t-il le système immunitaire ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affaiblir le système immunitaire et augmenter le risque de déplétion." } } ] } ] }

Sources (3875 au total)

Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia.

Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related...

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse disease biology and their inability to tolerate intensive therapy. We a... For this open-label phase 2 trial, patients aged 60 years or older with newly diagnosed, Philadelphia-chromosome negative, B-cell acute lymphocytic leukaemia, and an ECOG performance status of 3 or lo... Between Nov 11, 2011, and March 31, 2022, 80 patients were enrolled and treated (32 female and 48 male patients; median age 68 years [IQR 63-72]), 31 of whom were treated after the protocol amendment.... Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of progression-free survival in older patients with B-cell acute lymphocytic l... Pfizer and Amgen....

CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome.

Regular monitoring of CD34 donor chimerism (DC) is a highly sensitive method of predicting relapse in allogeneic stem cell transplant (alloHSCT) recipients with AML/MDS. A fall of CD34 DC below 80% is... We performed a retrospective analysis of consecutive alloHSCT patients between 2012 to 2023 who received DLI (with or without azacitidine) for CD34 MDC without morphologic relapse at the time of infus... Of the 21 patients with follow up CD34 DC available, 14 (66.7%) achieved CD34 full donor chimerism (FDC) following DLI with or without azacitidine (dli-FDC), while 7 (33.3%) did not (dli-MDC). The 2-y... Our study shows the restoration of CD34 FDC post-DLI is associated with reduced relapse and improved overall survival, with low NRM....

Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.

This meta-analysis aims to investigate the efficacy and safety of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) combined with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibit... Authors conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, Scopus, and Medline for randomized controlled trials comparing the prognosis and safety of PD-1/PD-L1 plus... A total of 4943 patients diagnosed with stage III/IV advanced or metastatic NSCLC were included in the analysis of the 6 randomized controlled trials. The results showed that patients receiving dual i... This meta-analysis demonstrates the effectiveness and safety of dual immunotherapy with PD-1/PD-L1 plus CTLA-4 inhibitors for treating advanced or metastatic NSCLC. Its efficacy is influenced by certa...

Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.

Dose-dense sequential (dds) chemotherapy has changed the clinical outcome of patients with early breast cancer (BC). To investigate the impact of dose intensity (DI) in the adjuvant setting of BC, thi... Totally, 1054 patients were prospectively enrolled in the current study with 1024 patients being eligible, while adequate tissue was available for 596 of them. TILs, CD8... Within a median follow-up of 125.18 months, a total of 200 disease-free survival (DFS) events (19.5%) were reported. Importantly, the 10-year DFS and OS rates were 78.4% (95% CI 75.0-81.5) and 81.7% (... In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs ...